Literature DB >> 15605675

Lipid-altering agents: the future.

A S Wierzbicki1.   

Abstract

Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605675     DOI: 10.1111/j.1742-1241.2004.00087.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  1 in total

1.  Design of nanovectors for therapy and imaging of cardiovascular diseases.

Authors:  Omolola Eniola-Adefeso; Michael J Heslinga; Tyrone M Porter
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.